Manning & Napier Group's EW Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 52 shares of Edwards Lifesciences Corporation (EW) worth $4,134, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Manning & Napier Group has initiated a new position in EW, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 29 shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's Edwards Lifesciences Corporation (EW) Holding Value Over Time
Track share changes against reported price movement
Quarterly Edwards Lifesciences Corporation (EW) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +29 | Add 126.09% | 52 | $79.50 |
| Q4 2025 | +23 | New Buy | 23 | $86.22 |
Manning & Napier Group's Edwards Lifesciences Corporation Investment FAQs
Manning & Napier Group first purchased Edwards Lifesciences Corporation (EW) in Q4 2025, acquiring 23 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held Edwards Lifesciences Corporation (EW) for 2 quarters since Q4 2025.
Manning & Napier Group's largest addition to Edwards Lifesciences Corporation (EW) was in Q1 2026, adding 52 shares worth $4,134.
According to the latest 13F filing for Q1 2026, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 52 shares of Edwards Lifesciences Corporation (EW), valued at approximately $4,134.
As of the Q1 2026 filing, Edwards Lifesciences Corporation (EW) represents approximately 0.00% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in Edwards Lifesciences Corporation (EW) was 52 shares, as reported at the end of Q1 2026.